# Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

> **NCT00676143** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 1100 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** bapineuzumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00676143
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-11
- **Target enrollment:** 1100 (ACTUAL)
- **Why stopped:** The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
- **Last updated:** 2016-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676143, "Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00676143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*